CAN UGT1A1 GENE POLYMORPHISM PREDICT TUMOR RESPONSIVENESS AFTER IRINOTECAN-BASED NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER?

被引：0
|
作者：
Choi, S.
Paek, O.
Oh, S.
Park, J.
Song, H.
Oh, D.
Suh, K.
机构：
来源：
DISEASES OF THE COLON & RECTUM | 2010年 / 53卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：613 / 613
页数：1
相关论文
共 50 条
  • [1] Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
    Lv, Tao
    Shen, Lijun
    Xu, Xiaoya
    Yao, Ye
    Mu, Peiyuan
    Zhang, Hui
    Wan, Juefeng
    Wang, Yan
    Guan, Ruoyu
    Li, Xiaomeng
    Fu, Guoxiang
    Zhang, Long
    Wang, Yaqi
    Xia, Fan
    Hu, Chen
    Clevers, Hans
    Zhang, Zhen
    Hua, Guoqiang
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (03) : 524 - 535
  • [2] UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
    Xu, Chunlei
    Tang, Xushan
    Qu, Yanli
    Keyoumu, Saifuding
    Zhou, Ning
    Tang, Yong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (01) : 119 - 130
  • [3] UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
    Chunlei Xu
    Xushan Tang
    Yanli Qu
    Saifuding Keyoumu
    Ning Zhou
    Yong Tang
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 119 - 130
  • [4] UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    Schulz, Christoph
    Heinemann, Volker
    Schalhorn, Andreas
    Moosmann, Nikolas
    Zwingers, Thomas
    Boeck, Stefan
    Giessen, Clemens
    Stemmler, Hans-Joachim
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (40) : 5058 - 5066
  • [5] UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    Christoph Schulz
    Volker Heinemann
    Andreas Schalhorn
    Nikolas Moosmann
    Thomas Zwingers
    Stefan Boeck
    Clemens Giessen
    Hans-Joachim Stemmler
    World Journal of Gastroenterology, 2009, 15 (40) : 5058 - 5066
  • [6] Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
    Liu, Xing-Han
    Lu, Jun
    Duan, Wei
    Dai, Zhi-Ming
    Wang, Meng
    Lin, Shuai
    Yang, Peng-Tao
    Tian, Tian
    Liu, Kang
    Zhu, Yu-Yao
    Zheng, Yi
    Sheng, Qian-Wen
    Dai, Zhi-Jun
    JOURNAL OF CANCER, 2017, 8 (04): : 691 - 703
  • [7] UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration
    Jiang, Pei-Cheng
    Wang, Shuo-Wen
    Li, Chao
    Fan, Jin
    Zhu, Ji
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (08) : 1484 - 1491
  • [8] UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
    Cote, Jean-Francois
    Kirzin, Sylvain
    Krarnar, Andrew
    Mosnier, Jean-Francois
    Diebold, Marie-Daniele
    Soubeyran, Isabelle
    Thirouard, Anne-Sophie
    Selves, Janick
    Laurent-Puig, Pierre
    Ychou, Marc
    CLINICAL CANCER RESEARCH, 2007, 13 (11) : 3269 - 3275
  • [9] The usefulness of UGT1A1 polymorphism testing before starting irinotecan-based chemotherapy.
    Harada, Taishi
    Saito, Haruhiro
    Sugiura, Makiko
    Murakami, Shuji
    Kondo, Tetsuro
    Oshita, Fumihiro
    Yamada, Kouzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare)
    Zhu, J.
    Chen, J.
    Zhu, Y.
    Zhou, J.
    Zhu, Y.
    Zhang, T.
    Jia, J.
    Zhang, C.
    Wang, X.
    Gao, Y.
    Cai, G.
    Luo, B.
    Wu, J.
    Liu, A.
    Xu, B.
    Zhang, Z.
    ANNALS OF ONCOLOGY, 2016, 27
12345